RecruitingNot Applicable

Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma

Italy83 participantsStarted 2022-09-01

Plain-language summary

The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase * Patients who have signed the informed consent form Exclusion Criteria: * Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years * Age \< 18 years * Women who are breastfeeding or pregnant * Patients with metal implants or devices that constitute an absolute contraindication for MRI * Patients with severe claustrophobia * Patients with bone pain that prevents prolonged maintenance of the supine position

What they're measuring

positivity rate

Timeframe: 33 months

Trial details

NCT IDNCT06659276

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-11

Contact for this trial

CRISTINA NANNI, MD

+390512143182 cristina.nanni@aosp.bo.it

View on ClinicalTrials.gov More Multiple Myeloma trials